ESTRO & EORTC Registry trial: OligoCare

Matthias Guckenberger, Piet Ost on behalf of the OligoCare project
OLIGOMETASTASES

Localized: Cure with local treatment
Oligometastatic: Cure with local treatment possible
Systemic: Local Tx for symptom control

The beauty: a simple concept
## Future evidence generation

<table>
<thead>
<tr>
<th>Future evidence generation</th>
</tr>
</thead>
<tbody>
<tr>
<td>primary tumour</td>
</tr>
<tr>
<td>type &amp; stage</td>
</tr>
<tr>
<td>treatment &amp; response</td>
</tr>
<tr>
<td>oligometastases</td>
</tr>
<tr>
<td>definition &amp; diagnosis</td>
</tr>
<tr>
<td>timing</td>
</tr>
<tr>
<td>numbers &amp; size</td>
</tr>
<tr>
<td>nodal vs. distant organs &amp; location</td>
</tr>
<tr>
<td>treatment</td>
</tr>
<tr>
<td>dose &amp; fractionation</td>
</tr>
<tr>
<td>technique &amp; technology</td>
</tr>
<tr>
<td>other treatment modalities</td>
</tr>
<tr>
<td>trial &amp; endpoints</td>
</tr>
<tr>
<td>survival vs. intermediary endpoints</td>
</tr>
<tr>
<td>QOL &amp; PROMs</td>
</tr>
<tr>
<td>cost data</td>
</tr>
</tbody>
</table>
OligoCare

A Pragmatic Observational Basket Study to Evaluate Radical Radiotherapy for Oligo-Metastatic Cancer Patients
Study Objectives

- To assess patterns-of-care and patterns-of-outcome of stereotactic radiotherapy for oligometastatic disease

- To identify patient, tumor and treatment characteristics influencing safety and efficacy
Benefits from participation

- Participation open to ALL radiotherapy centres, not "ONLY" EORTC members of academic institutions (participating countries tbd based on feasibility survey)
- Open and transparent data sharing policy
  - All participating centres can apply for data access and research projects
- Possibility of regular benchmarking of your institution
  - optional AND anonymous
- Consideration in all publications, considering active participation
- Certification as participating institution
- Increase in study activity and increase in proportion of patients in clinical trials
- …..
OligoCare: inclusion criteria

- Patients are eligible irrespective whether oligometastatic disease is diagnosed synchronously or metachronously.
- There are no restrictions with respect to prior surgical, locally ablative, radiotherapy and systemic treatments performed.
- ALL visible cancer lesions (loco-regional primary and all oligometastases) are treated with radical intent. There is no upper limit of metastases treated radically.
- Radical radiotherapy must be a component of treatment of oligometastases.
- Primary disease types: non small cell lung cancer, breast cancer, prostate cancer, colorectal cancer.
OligoCare: Study Design

WP 1
- Lung
- Breast
- Prostate
- Colorectal
- Melanoma
- ....

WP 2
Common Data Elements collected across diseases + tumor type-specific data collection

WP 3
- Ablative Radiotherapy Treatment
- Follow-up to death or lost to follow-up
- Imaging & lab
- Disease outcome, QOL & Cost
OligoCare: data collection & storage

- EORTC sites
- Cancer Registries
- Data from previous studies
- Health insurance companies
- ESTRO members (institutional)
- National Societies

Pragmatic Observational Basket Study

Institutional data

Prospective & retrospective
Current status

• Protocol finished

• e-CRF in development

• Feasibility survey distributed during / after this ESTRO meeting
Interested ? – please register !

OligoCare - Pragmatic Observational Basket Study to Evaluate Radical Radiotherapy for Oligo-Metastatic Cancer Patients

Interested to participate? Register at:

https://eortc.wufoo.eu/forms/samy6re10j7jz0/
CONCLUSIONS

• SBRT for oligo-metastases has arrived as a standard of care,
  • despite lack of hard evidence
  • despite huge uncertainties & variability in practice

• Traditional clinical trials will not answer all answers

• OligoCare:
  • Joint initiative between ESTRO & EORTC
  • Collaborative, Global, Pragmatic, Adaptive
Thank you for your attention, and looking forward to our collaboration!

Matthias Guckenberger
Yolande Lievens
Umberto Riccardi
Dirk Verellen
Alejandra Mendez Romero
Martra Scorsetti
Christine Verfaillie

Piet Ost
Laurence Collette
Sandra Collette
Beatrice Fournier
Coen Hurkmans
Yan Liu
Bertrand Tombal